Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06742723RecruitingPhase 3
Study of baxdrostat and dapagliflozin for kidney disease and high blood pressure
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
Fairhope, AlabamaAges 18 years+ - NCT06747949RecruitingPhase 3
Long term extension study of dazodalibep for Sjogren's syndrome
This study gives continued access to the study drug dazodalibep for people with Sjogren's syndrome who completed a prior phase 3 study. The goal is to see how safe and effective the medication is over a longer period.
Avondale, ArizonaAges 18 years+ - NCT06741644RecruitingPhase 1/Phase 2
CS2009 for advanced solid tumors
This trial tests a new drug called CS2009 for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06739122RecruitingPhase 3
A study of dulaglutide for children with type 2 diabetes
This trial tests if a weekly injection of dulaglutide (Trulicity) can help children with type 2 diabetes control their blood sugar when used together with metformin and/or insulin. It may be an option for kids who are overweight.
Tucson, ArizonaAges 10–17 - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT06745375Enrolling by invitation
Soft contact lens fit and power study
This study looks at how soft contact lenses fit on the eye and how their power affects vision. It may help you if you wear or want to try soft contact lenses.
Birmingham, UKAges 18–60 - NCT06417008RecruitingPhase 2/Phase 3
Combination targeted therapy for advanced EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06463340RecruitingPhase 1
Study of SGR-3515 for advanced solid tumors
This trial tests a new drug called SGR-3515 for people with advanced solid tumors. It aims to see if the drug is safe and how it works in the body.
New Haven, ConnecticutAges 18 years+ - NCT06727604RecruitingPhase 2
Study of IMVT-1402 for Graves' disease not controlled by medication
This trial tests a new drug called IMVT-1402 for adults with Graves' disease whose thyroid is still overactive despite taking antithyroid medication. The goal is to see if the drug can safely help control thyroid hormone levels.
Phoenix, ArizonaAges 18–75 - NCT06735248RecruitingPhase 2
Study testing mRNA vaccine for multiple sclerosis relapse prevention
This study tests whether an mRNA vaccine (mRNA-1195) can help prevent relapses in people with early relapsing multiple sclerosis (MS). It compares the vaccine to a placebo (a shot with no active ingredient) to see if it is safe and effective.
Boston, MassachusettsAges 18–55 - NCT06736704RecruitingPhase 1/Phase 2
Study of SNV4818 for advanced solid tumors with PIK3CA mutation
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06734351RecruitingPhase 3
Comparing two gels for cheek fullness
This study tests a new injectable gel (NOA VOLUME) for restoring fullness in the cheeks, comparing it to an already-approved gel (JUVÉDERM VOLUMA XC). It's for adults with moderate to severe cheek hollowing who want a safe, effective option.
Birmingham, AlabamaAges 22 years+ - NCT06114043Recruiting
Surgery vs. non-surgery for mild to moderate bunion pain
This trial compares two approaches for treating mild-to-moderate bunion pain: surgery versus non-surgical options like wearing wider shoes, toe spacers, or physical therapy. The goal is to see which works better for relieving pain and improving daily life.
SarpsborgAges 18–80 - NCT06718387Recruiting
Psycho-education program for sexual violence victims
This trial studies whether a psycho-education program (learning about trauma and coping) helps victims of sexual violence who are being treated at a specific clinic. It aims to understand if taking part in this program improves well-being.
BordeauxAges 18–75 - NCT06721494RecruitingPhase 2
A single-dose study of CS-1103 for methamphetamine use
This trial tests a single dose of an investigational drug, CS-1103, to see if it is safe and effective for people who use methamphetamine. It may help understand how the drug affects methamphetamine in the body.
Glendale, CaliforniaAges 18–55 - NCT06721013RecruitingPhase 1/Phase 2
Study of Pirtobrutinib for immune thrombocytopenia
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06721143RecruitingPhase 1/Phase 2
Study of AION-301 for chronic kidney disease
This trial tests an experimental drug called AION-301 for people with chronic kidney disease (CKD). The goal is to see if it's safe and may help slow kidney decline. It's given by IV infusion and compared to a placebo (inactive infusion).
Miami, FloridaAges 35–75 - NCT06723236RecruitingPhase 1
Study of MGC028 for Advanced Solid Tumors
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06717932Enrolling by invitation
Long-term safety study of CS-101 injection
This study follows up with people who already received the CS-101 injection in a previous trial to check its safety and how well it works over time.
NanningAges 12–35 - NCT06726369RecruitingPhase 1
Experimental drug for advanced solid tumors
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
Xiamen, FujianAges 18 years+ - NCT06722352Recruiting
Palliative care education for dementia in assisted living
This study trains staff in assisted living facilities to better support residents with dementia and their families in planning future care. It focuses on helping families talk about advance care planning (decisions about future medical care) with the care team.
Tampa, FloridaAges 21 years+ - NCT06716138RecruitingPhase 1
ANS03 for solid tumors with ROS1 or NTRK changes
This trial tests a new drug called ANS03 for people with certain genetic changes (ROS1 or NTRK) in their solid tumors. The goal is to see if ANS03 can shrink or slow the cancer.
New York, New YorkAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,283 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.